BlackRock’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$638M Buy
10,971,816
+725,438
+7% +$39.4M 0.01% 939
2025
Q4
$473M Buy
10,246,378
+290,400
+3% +$13M 0.01% 1141
2025
Q3
$359M Sell
9,955,978
-686,265
-6% -$22.7M 0.01% 1298
2025
Q2
$346M Buy
10,642,243
+62,766
+0.6% +$2.06M 0.01% 1270
2025
Q1
$399M Sell
10,579,477
-526,592
-5% -$42.1M 0.01% 1175
2024
Q4
$909M Buy
11,106,069
+439,632
+4% +$43.7M 0.02% 699
2024
Q3
$1.22B Buy
10,666,437
+726,591
+7% +$65.5M 0.03% 546
2024
Q2
$751M Buy
9,939,846
+426,839
+4% +$29.1M 0.02% 744
2024
Q1
$650M Buy
9,513,007
+937,160
+11% +$64.9M 0.02% 847
2023
Q4
$539M Buy
8,575,847
+1,154,596
+16% +$60M 0.01% 950
2023
Q3
$378M Buy
7,421,251
+356,163
+5% +$17.6M 0.01% 1093
2023
Q2
$353M Buy
7,065,088
+1,983,223
+39% +$94M 0.01% 1170
2023
Q1
$190M Sell
5,081,865
-23,505
-0.5% -$997K 0.01% 1574
2022
Q4
$245M Buy
5,105,370
+1,613,049
+46% +$63.3M 0.01% 1379
2022
Q3
$83.8M Buy
3,492,321
+220,691
+7% +$5.59M ﹤0.01% 2085
2022
Q2
$71.2M Buy
3,271,630
+385,608
+13% +$8.92M ﹤0.01% 2251
2022
Q1
$69.7M Buy
2,886,022
+108,975
+4% +$2.38M ﹤0.01% 2367
2021
Q4
$66.1M Buy
2,777,047
+252,402
+10% +$5.87M ﹤0.01% 2473
2021
Q3
$64.1M Buy
2,524,645
+178,028
+8% +$4.32M ﹤0.01% 2502
2021
Q2
$52.8M Buy
2,346,617
+157,889
+7% +$3.23M ﹤0.01% 2663
2021
Q1
$43.2M Buy
2,188,728
+495,700
+29% +$12.5M ﹤0.01% 2712
2020
Q4
$45M Buy
1,693,028
+688,500
+69% +$25.6M ﹤0.01% 2541
2020
Q3
$49.6M Buy
1,004,528
+924,716
+1,159% +$36.8M ﹤0.01% 2308
2020
Q2
$2.52M Buy
+79,812
New +$2.57M ﹤0.01% 3764

Other funds holding PCVX